Adjusted RR for quartile levels of creatinine-adjusted melatonin (ng/mg of creatinine) for all breast cancer combined and for ER+ breast cancer alone by time interval between urinary collection and diagnosis
| Cases | Controls | RR (95% CI) | Ptrend | RRa (95% CI) | Ptrend | |
|---|---|---|---|---|---|---|
| All cases, ≤4 y | ||||||
| Q1 (<6.69) | 17 | 46 | 1.0 (ref.) | 0.18 | 1.0 (ref.) | 0.11 |
| Q2 [6.69–12.81) | 21 | 43 | 1.37 (0.63–3.01) | 1.25 (0.51–3.06) | ||
| Q3 [12.81–22.18) | 21 | 35 | 1.71 (0.77–3.83) | 1.85 (0.75–4.57) | ||
| Q4 (≥22.18) | 21 | 36 | 1.69 (0.74–3.84) | 1.94 (0.75–5.03) | ||
| All cases, >4 y | ||||||
| Q1 (<6.69) | 38 | 74 | 1.0 (ref.) | 0.93 | 1.0 (ref.) | 0.89 |
| Q2 [6.69–12.81) | 36 | 79 | 0.89 (0.52–1.53) | 0.97 (0.54–1.75) | ||
| Q3 [12.81–22.18) | 48 | 84 | 1.12 (0.65–1.91) | 1.09 (0.60–1.97) | ||
| Q4 (≥22.18) | 37 | 80 | 0.90 (0.52–1.56) | 1.00 (0.55–1.83) | ||
| ER+ cases, ≤ 4 y | ||||||
| Q1 (<6.69) | 14 | 30 | 1.0 (ref) | 0.65 | 1.0 (ref) | 0.72 |
| Q2 [6.69–12.81) | 13 | 31 | 0.94 (0.36–2.46) | 0.64 (0.20–2.04) | ||
| Q3 [12.81–22.18) | 15 | 22 | 1.49 (0.55–4.03) | 1.49 (0.50–4.43) | ||
| Q4 (≥22.18) | 12 | 25 | 1.10 (0.39–3.13) | 0.90 (0.27–2.95) | ||
| ER+ cases, >4 y | ||||||
| Q1 (<6.69) | 28 | 51 | 1.0 (ref.) | 0.71 | 1.0 (ref.) | 0.72 |
| Q2 [6.69–12.81) | 32 | 65 | 0.90 (0.49–1.64) | 0.94 (0.50–1.79) | ||
| Q3 [12.81–22.18) | 34 | 69 | 0.89 (0.47–1.66) | 0.82 (0.41–1.63) | ||
| Q4 (≥22.18) | 28 | 58 | 0.88 (0.46–1.68) | 0.92 (0.46–1.83) | ||
Abbreviation: RR, relative risk.
↵aAdjusted for body mass index, education, and bilateral oophorectomy.